Floatz logo

Aph-1105

Alzheimer Disease 3

AphiosPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Alzheimer Disease 3 cohort.

Asset / SponsorPhaseRating
Lacosamide
Xiangya Hospital of Central South University
Phase 4BB
2-Bromo-?-ergocryptine
Kyoto University
Phase 1/2CCC

Same molecule, other indications

Aph-1105 is also rated in:

dementiaDormant
CCC
Indicative ·
53 / 100
View asset →
Alzheimer disease type 1Dormant
CCC
Indicative ·
53 / 100
View asset →
Alzheimer disease 2Dormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →